Elanco Animal Health (ELAN) Expected to Announce Quarterly Earnings on Tuesday

Elanco Animal Health (NYSE:ELAN) will likely be releasing its earnings data before the market opens on Tuesday, February 25th. Analysts expect Elanco Animal Health to post earnings of $0.16 per share and revenue of $1.01 billion for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Elanco Animal Health Trading Down 3.4 %

ELAN stock opened at $11.26 on Tuesday. Elanco Animal Health has a 52 week low of $10.77 and a 52 week high of $18.80. The company’s 50-day simple moving average is $11.90 and its 200 day simple moving average is $13.13. The company has a market capitalization of $5.57 billion, a PE ratio of 28.15, a price-to-earnings-growth ratio of 2.69 and a beta of 1.42. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Leerink Partners started coverage on Elanco Animal Health in a research report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price target on the stock. UBS Group assumed coverage on shares of Elanco Animal Health in a research report on Monday, December 9th. They set a “buy” rating and a $18.00 price objective for the company. Morgan Stanley lowered their price target on shares of Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating for the company in a report on Wednesday, January 29th. Leerink Partnrs raised Elanco Animal Health to a “hold” rating in a report on Monday, December 2nd. Finally, Stifel Nicolaus lowered their target price on Elanco Animal Health from $20.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $16.29.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.